Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes: The Thousand and 1 Study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes : The Thousand and 1 Study. / Rørth, Rasmus; Jørgensen, Peter Godsk; Andersen, Henrik Ullits; Christoffersen, Christina; Gøtze, Jens Peter; Køber, Lars; Rossing, Peter; Jensen, Magnus Thorsten.

In: European Journal of Endocrinology, Vol. 182, No. 5, 01.03.2020, p. 481-488.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Rørth, R, Jørgensen, PG, Andersen, HU, Christoffersen, C, Gøtze, JP, Køber, L, Rossing, P & Jensen, MT 2020, 'Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes: The Thousand and 1 Study', European Journal of Endocrinology, vol. 182, no. 5, pp. 481-488. https://doi.org/10.1530/EJE-19-1015

APA

Rørth, R., Jørgensen, P. G., Andersen, H. U., Christoffersen, C., Gøtze, J. P., Køber, L., ... Jensen, M. T. (2020). Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes: The Thousand and 1 Study. European Journal of Endocrinology, 182(5), 481-488. https://doi.org/10.1530/EJE-19-1015

Vancouver

Rørth R, Jørgensen PG, Andersen HU, Christoffersen C, Gøtze JP, Køber L et al. Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes: The Thousand and 1 Study. European Journal of Endocrinology. 2020 Mar 1;182(5):481-488. https://doi.org/10.1530/EJE-19-1015

Author

Rørth, Rasmus ; Jørgensen, Peter Godsk ; Andersen, Henrik Ullits ; Christoffersen, Christina ; Gøtze, Jens Peter ; Køber, Lars ; Rossing, Peter ; Jensen, Magnus Thorsten. / Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes : The Thousand and 1 Study. In: European Journal of Endocrinology. 2020 ; Vol. 182, No. 5. pp. 481-488.

Bibtex

@article{8073e03bb2804c74a099dad03207529c,
title = "Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes: The Thousand and 1 Study",
abstract = "Aims Patients with type 1 diabetes have a high risk of cardiovascular disease. Yet, the importance of routine assessment of myocardial function in patients with type 1 diabetes is not known. Thus, we examined the prognostic importance of NT-proBNP and E/e', an echocardiographic measure of diastolic function, in type 1 diabetes patients with preserved left ventricular ejection fraction (LVEF) and without known heart disease. Methods and Results Type 1 diabetes patients without known heart disease and LVEF ≥ 45{\%} enrolled in the Thousand and1 study were included and followed through nationwide registries. The risk of major cardiovascular events (MACE) and death associated with levels of NT-proBNP and E/e' was examined. Of 960 patients, median follow-up of 6.3 years (Q1-Q3: 5.7-7.0), 121 (12{\%}) experienced MACE and 51 (5{\%}) died. Increased levels of both NT-proBNP and E/e' were associated with worse outcomes (adjusted hazard ratios for MACE = 1.56 (1.23-1.98) and 4.29 (2.25-8.16) per Loge increase for NT-proBNP and E/e', respectively). NTproBNP and E/e' combined significantly improved the discrimination power of the Steno T1D risk engine (MACE, C-index: 0.813 (0.779-0.847) vs 0.779 (0.742-0.816); P=0.0001; All-cause mortality, C-index 0.855 (0.806-0.903) vs 0.828 (0.776-0.880); P=0.03). Conclusion In patients with type 1 diabetes, preserved ejection fraction, and no known heart disease, NT-proBNP and E/e' were associated with increased risk of MACE and all-cause mortality. The risks associated with NT-proBNP and E/e' combined identified patients at remarkably high risk.",
author = "Rasmus R{\o}rth and J{\o}rgensen, {Peter Godsk} and Andersen, {Henrik Ullits} and Christina Christoffersen and G{\o}tze, {Jens Peter} and Lars K{\o}ber and Peter Rossing and Jensen, {Magnus Thorsten}",
year = "2020",
month = "3",
day = "1",
doi = "10.1530/EJE-19-1015",
language = "English",
volume = "182",
pages = "481--488",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "5",

}

RIS

TY - JOUR

T1 - Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes

T2 - The Thousand and 1 Study

AU - Rørth, Rasmus

AU - Jørgensen, Peter Godsk

AU - Andersen, Henrik Ullits

AU - Christoffersen, Christina

AU - Gøtze, Jens Peter

AU - Køber, Lars

AU - Rossing, Peter

AU - Jensen, Magnus Thorsten

PY - 2020/3/1

Y1 - 2020/3/1

N2 - Aims Patients with type 1 diabetes have a high risk of cardiovascular disease. Yet, the importance of routine assessment of myocardial function in patients with type 1 diabetes is not known. Thus, we examined the prognostic importance of NT-proBNP and E/e', an echocardiographic measure of diastolic function, in type 1 diabetes patients with preserved left ventricular ejection fraction (LVEF) and without known heart disease. Methods and Results Type 1 diabetes patients without known heart disease and LVEF ≥ 45% enrolled in the Thousand and1 study were included and followed through nationwide registries. The risk of major cardiovascular events (MACE) and death associated with levels of NT-proBNP and E/e' was examined. Of 960 patients, median follow-up of 6.3 years (Q1-Q3: 5.7-7.0), 121 (12%) experienced MACE and 51 (5%) died. Increased levels of both NT-proBNP and E/e' were associated with worse outcomes (adjusted hazard ratios for MACE = 1.56 (1.23-1.98) and 4.29 (2.25-8.16) per Loge increase for NT-proBNP and E/e', respectively). NTproBNP and E/e' combined significantly improved the discrimination power of the Steno T1D risk engine (MACE, C-index: 0.813 (0.779-0.847) vs 0.779 (0.742-0.816); P=0.0001; All-cause mortality, C-index 0.855 (0.806-0.903) vs 0.828 (0.776-0.880); P=0.03). Conclusion In patients with type 1 diabetes, preserved ejection fraction, and no known heart disease, NT-proBNP and E/e' were associated with increased risk of MACE and all-cause mortality. The risks associated with NT-proBNP and E/e' combined identified patients at remarkably high risk.

AB - Aims Patients with type 1 diabetes have a high risk of cardiovascular disease. Yet, the importance of routine assessment of myocardial function in patients with type 1 diabetes is not known. Thus, we examined the prognostic importance of NT-proBNP and E/e', an echocardiographic measure of diastolic function, in type 1 diabetes patients with preserved left ventricular ejection fraction (LVEF) and without known heart disease. Methods and Results Type 1 diabetes patients without known heart disease and LVEF ≥ 45% enrolled in the Thousand and1 study were included and followed through nationwide registries. The risk of major cardiovascular events (MACE) and death associated with levels of NT-proBNP and E/e' was examined. Of 960 patients, median follow-up of 6.3 years (Q1-Q3: 5.7-7.0), 121 (12%) experienced MACE and 51 (5%) died. Increased levels of both NT-proBNP and E/e' were associated with worse outcomes (adjusted hazard ratios for MACE = 1.56 (1.23-1.98) and 4.29 (2.25-8.16) per Loge increase for NT-proBNP and E/e', respectively). NTproBNP and E/e' combined significantly improved the discrimination power of the Steno T1D risk engine (MACE, C-index: 0.813 (0.779-0.847) vs 0.779 (0.742-0.816); P=0.0001; All-cause mortality, C-index 0.855 (0.806-0.903) vs 0.828 (0.776-0.880); P=0.03). Conclusion In patients with type 1 diabetes, preserved ejection fraction, and no known heart disease, NT-proBNP and E/e' were associated with increased risk of MACE and all-cause mortality. The risks associated with NT-proBNP and E/e' combined identified patients at remarkably high risk.

U2 - 10.1530/EJE-19-1015

DO - 10.1530/EJE-19-1015

M3 - Journal article

C2 - 32209724

VL - 182

SP - 481

EP - 488

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 5

ER -

ID: 239255676